Biochemical pharmacology

GLP-1 Peptide Drugs: Moving from Shots to Oral Pills

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Peptide glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective for treating type 2 diabetes and have heart and kidney benefits.

  • Oral semaglutide is the only GLP-1RA that does not require injection but has low bioavailability and can cause gastrointestinal discomfort.
  • Other GLP-1RAs need to be administered via injection, which may limit patient compliance.
  • Exploring advanced oral delivery strategies for peptide GLP-1RAs is essential due to the challenges faced by oral semaglutide.
  • The review compares the advantages and disadvantages of various oral delivery methods currently in development for peptide GLP-1RAs.
  • Recent research progress on peptide GLP-1RAs is discussed to support the development of new oral formulations.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

Related papers

Jul '21
Clinical views on using under-the-skin versus oral forms of semaglutide
top 10% journal
cited by 61 papers
research support, non-u.s. gov't
Mar '24
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
top 30% journal
cited by 10 papers
observational study
Aug '20
Using GLP-1 receptor drugs for type 2 diabetes: their role and clinical experience so far
cited by 68 papers
video-audio media
Aug '20
Effectiveness and safety of oral semaglutide for people with type 2 diabetes starting injectable treatment or already using insulin
cited by 22 papers
video-audio media
Aug '20
Long-lasting GLP-1 receptor drugs: effectiveness, safety, and use in managing type 2 diabetes
cited by 39 papers
journal article
Dec '16
Effectiveness and safety of glucagon-like peptide-1 drugs for type 2 diabetes
cited by 381 papers
systematic review
Aug '20
Using oral semaglutide in primary care: who should take it, when, and how
cited by 21 papers
video-audio media
Oct '23
Tirzepatide's effects on blood sugar control and weight loss compared to similar medicines in Japanese people with type 2 diabetes
cited by 16 papers
systematic review
Jul '22
Using SNAC to develop oral semaglutide for treating type 2 diabetes
top 5% journal
cited by 90 papers
research support, non-u.s. gov't
May '24
Low use of GLP-1 receptor drugs for type 2 diabetes despite their good benefits and safety
top 30% journal
cited by 14 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
yesterday7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
1 week ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
2 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
3 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
4 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
5 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
6 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
7 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
8 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief